EXSCIENTIA
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit.
“We want to be as innovative in the clinic as we have been in drug discovery. Mike is a proven innovator and strategic leader at the vanguard of bringing a quantitative science approach to clinical development. He has been a thought leader in the field for more than 20 years, implementing model-informed drug development, increasing the use of biomarkers to enable adaptive trials, and finding better ways to enrich trials for patient selection,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “Focusing our clinical trials on the people that are most likely to benefit from them has the potential to not only improve clinical success rates, but it also advances our mission of putting patients at the centre of creating new medicines.”
Dr. Krams joins Exscientia’s executive leadership team, reporting to Andrew Hopkins, and will be based at Exscientia’s precision medicine centre in Vienna, Austria. Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier in his career, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.
“I’m pleased to join Exscientia, a mission-driven company harnessing artificial intelligence to transform drug discovery and development to make better medicines for patients. In many ways, the work I’ve driven throughout my career is a good match to Exscientia’s goal - asking how conventional, sequential approaches to clinical development can be further improved, aiming for truly patient-driven medicine development. Discovery and clinical strategies need to be closely connected through biomarker strategies and Exscientia’s precision medicine platform has the potential to achieve just that,” said Mike Krams, M.D., Chief Quantitative Medicine Officer for Exscientia.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI .
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding its management team. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the drug discovery and precision medicine platforms discussed above will be successful in optimising drug candidates for specific patient populations. The success of Exscientia’s platforms is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the ability of Exscientia to design clinical trials that are cleared by the FDA and of healthcare providers to collect viable patient tissue samples. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005276/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapyd’s 2026 State of Stablecoins: Businesses Move En Masse as Stablecoins Go Mainstream14.1.2026 14:00:00 CET | Press release
Rapyd’s 2026 State of Stablecoins Report shows 64% of businesses surveyed already use stablecoins or plan to within three years, with speed, easier cross-border transactions, and cost savings driving adoption Rapyd, a leading global fintech company, released its 2026 State of Stablecoins Report, revealing that stablecoins have reached a tipping point and are becoming a foundational component of global commerce rather than a niche digital asset. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114427729/en/ Rapyd research shows 64% of businesses already use stablecoins or plan to within three years, as speed, cross-border efficiency, and cost savings drive mainstream adoption. The report shows the market has moved decisively into active, real-world use. Today, nearly one in five businesses already consider stablecoins a mainstream financial tool. Looking ahead, a much larger majority (76%) believe stablecoins are either alre
WEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I–IV Trial Delivery Capabilities14.1.2026 14:00:00 CET | Press release
WEP Clinical (WEP), a full-service contract research organization (CRO), announces the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP’s global footprint and strengthens its ability to deliver end-to-end Phase I–IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and has a strong track record in orphan diseases, pediatric research, and medical device trials. Jaswinder Khera, WEP Founder and CEO, said: “This acquisition represents a significant milestone in
Armis Launches New Partner Program, Expanding its Reach to Help Global Organizations Enhance Cyber Resilience14.1.2026 14:00:00 CET | Press release
Company deepens partner-first strategy, empowering partners to grow with Armis in a way that best fits their unique business needs without tiers or requirements Armis, the cyber exposure management & security company, today announced the launch of the Armis Select Partner Program. The new program marks a significant evolution in Armis' commitment to its global partner ecosystem. By extending the reach of Armis Centrix™, the Armis Cyber Exposure Management Platform, to organizations worldwide through its partner program, joint customers can streamline their security operations and proactively strengthen defenses. “Global enterprises don’t just need tools; they need a unified ecosystem of trusted partners to navigate an increasingly volatile threat landscape,” said Alex Mosher, President and CRO of Armis. “At Armis, our partners are the primary engine of our growth and the cornerstone of our global strategy. By evolving our partner program, we are doubling down on this collaborative foun
Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure14.1.2026 13:00:00 CET | Press release
Alpaca appoints lead investor Drive Capital’s Co-Founder and Partner Chris Olsen to its board Alpaca, a global leader in brokerage infrastructure whose APIs empower partners like Kraken, SBI Securities, and Dime!, today announced it has raised a $150 million Series D led by Drive Capital that values the company at $1.15 billion. Drive Capital’s Co-Founder and Partner, Chris Olsen, will join Alpaca’s Board of Directors as part of the investment. The company also secured a $40 million line of credit, further strengthening its balance sheet as it continues to expand globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114225657/en/ Alpaca Raises $150 Million at a $1.15B Valuation to Build the Global Standard for Brokerage Infrastructure “Our mission is to open financial services to everyone on the planet,” said Yoshi Yokokawa, Co-Founder and CEO of Alpaca. “We are building the global standard for brokerage infrastructure
Sixth Street Raises €3.75 Billion for Third European Direct Lending Fund14.1.2026 12:30:00 CET | Press release
Sixth Street SLE III Hits Hard Cap, Reflecting Long-Term Strength as One of Europe’s Leading Private Capital Platforms Sixth Street, a leading global investment firm, today announced the final close of Sixth Street Specialty Lending Europe III (“SLE III” or “the Fund”), at its hard cap with €3.75 billion in total equity commitments. SLE III is Sixth Street’s third and largest dedicated fund focused on providing financing solutions for companies across Europe. The total investable capital for SLE III is expected to be approximately €7 billion, including anticipated leverage. “We are grateful to our long-term capital partners for their trust and commitment to our strategy as we continue to support European businesses at any point in their lifecycle, offering customized capital solutions delivered with speed and certainty,” said Michael Griffin, Co-Head of Sixth Street Global Direct Lending and Head of Europe Direct Lending. “This is a significant milestone for our European Direct Lending
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom